VANCOUVER, April 17, 2015 /CNW/ - iCo Therapeutics Inc.
("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), at the
request of IIROC, confirms that there is no material change that
would account for the recent increase in market activity.
About iCo Therapeutics
iCo Therapeutics in-licenses
and redefines existing drug candidates or generics by employing
reformulation and delivery technologies for new or expanded use
indications. The Company has exclusive worldwide rights to two drug
candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008
for other sight-threatening diseases. iCo-007 is in Phase 2
clinical studies for DME. With Phase 2 clinical history,
Bertilimumab (iCo-008) is targeted for the treatment of
keratoconjunctivitis and wet age-related macular degeneration. In
addition, iCo holds worldwide rights to an oral drug delivery
platform. The first platform candidate is the Oral Amp B Delivery
system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX Venture
Exchange under the symbol "ICO" and the OTCQX under the symbol
"ICOTF". For more information, visit the Company website at:
www.icotherapeutics.com.
No regulatory authority has approved or disapproved the
content of this press release. Neither the TSX Venture Exchange nor
its Regulatory Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
Forward Looking Statements
Certain statements
included in this press release may be considered forward-looking
statements" within the meaning of applicable securities laws.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will," and similar references to future periods.
Such statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. All forward-looking
statements are based on iCo's current beliefs as well as
assumptions made by and information currently available to iCo and
relate to, among other things, anticipated financial performance,
business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to
place undue reliance on these forward-looking statements, which are
based only on information currently available to iCo and speak only
as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
iCo in its public securities filings and on its website, actual
events may differ materially from current expectations. iCo
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
SOURCE iCo Therapeutics Inc.
